2026 Q2 -tulosraportti
UUTTA
3 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 9 455 | - | - | ||
| 100 | - | - | ||
| 5 000 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 t sittenTHERE ARE MANY STOCKS WITH ENORMOUS UPSIDE. THAT IS NOT WHAT MAKES CIRCIO SPECIAL. 🧬 Find a biotech that can go 20x? Not difficult. The problem is what you usually get with the deal: → One lead program → Short runway → New capital raise around the corner → Limited external validation → Binary clinical risk → And a technology that in practice lives or dies with one indication What's interesting about Circio is the combination. A still small company now has: A platform technology. Extreme preclinical expression data across multiple tissues. 20+ external R&D collaborations. A top-5 pharma that has already taken circVec further in vivo. AAV + LNP + in-vivo cell therapy. And after the capital raise: runway until 2030. It's a rather strange setup. Too much has already happened for this to just be an idea on PowerPoint. But the really big value drivers are still ahead: Disease efficacy. NHP. Paid agreements. Human validation. It is precisely between these two points that the truly asymmetric cases can exist: Enough validation that the technology deserves attention. But still early enough that the market doesn't price in what it could become. Are there other biotechs with enormous upside? Of course. Are there many with exactly this combination of platform + data + Big Pharma interest + optionality + financing, while still being small? There, the list suddenly becomes much shorter. That's why I follow Circio so extremely closely. Not because the outcome is guaranteed. But because such setups don't appear every day. 🧬 We know what we own. 🧱♟️🍷
·5 t sitten · MuokattuMany thanks to all contributors here 🙏 You possess a lot of expertise that we benefit from. This is the most exciting Biotech company on OSE. Believe this can multiply several times next year. Unbelievably many positive triggers ahead of us. But remember that negative news briefly pushes the price down. I am long. 💰🇧🇻. I took a nice profit in Wawi and will receive kr 51,678 in dividends from there in a few days, which helps a bit. So I saw I slammed in K500' more into CRNA. I, like you, am a super optimist.⛵⛵⛵Greetings from the skipper 🎊🤠
·6 t sittenHappy weekend, fam! ❤️ now we can relax and enjoy the weekend, after an eventful week 😃 have never had more faith in Circio, than now! The last half year has tested nerves and wallet, but has been enormously educational. Appreciate all the great posts here, both those that make me smile, and those that share knowledge and useful information. Mostly a fantastic bunch, who are eager to acquire information and knowledge💪 It is clear that this stock tests many people's nerves, and the wise posts in the forum probably help calm many down, so thank you all, for everything you contribute 😘 appreciate you!
·7 t sittenHow to invest in Circio: 1. Not know a damn thing about what the company is doing 2. Buy when the stock peaks 3. Sell when the stock hits rock bottom (Repeat points 2. and 3.) 4. Whine in the Nordnet forums
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
3 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenTHERE ARE MANY STOCKS WITH ENORMOUS UPSIDE. THAT IS NOT WHAT MAKES CIRCIO SPECIAL. 🧬 Find a biotech that can go 20x? Not difficult. The problem is what you usually get with the deal: → One lead program → Short runway → New capital raise around the corner → Limited external validation → Binary clinical risk → And a technology that in practice lives or dies with one indication What's interesting about Circio is the combination. A still small company now has: A platform technology. Extreme preclinical expression data across multiple tissues. 20+ external R&D collaborations. A top-5 pharma that has already taken circVec further in vivo. AAV + LNP + in-vivo cell therapy. And after the capital raise: runway until 2030. It's a rather strange setup. Too much has already happened for this to just be an idea on PowerPoint. But the really big value drivers are still ahead: Disease efficacy. NHP. Paid agreements. Human validation. It is precisely between these two points that the truly asymmetric cases can exist: Enough validation that the technology deserves attention. But still early enough that the market doesn't price in what it could become. Are there other biotechs with enormous upside? Of course. Are there many with exactly this combination of platform + data + Big Pharma interest + optionality + financing, while still being small? There, the list suddenly becomes much shorter. That's why I follow Circio so extremely closely. Not because the outcome is guaranteed. But because such setups don't appear every day. 🧬 We know what we own. 🧱♟️🍷
- ·5 t sitten · MuokattuMany thanks to all contributors here 🙏 You possess a lot of expertise that we benefit from. This is the most exciting Biotech company on OSE. Believe this can multiply several times next year. Unbelievably many positive triggers ahead of us. But remember that negative news briefly pushes the price down. I am long. 💰🇧🇻. I took a nice profit in Wawi and will receive kr 51,678 in dividends from there in a few days, which helps a bit. So I saw I slammed in K500' more into CRNA. I, like you, am a super optimist.⛵⛵⛵Greetings from the skipper 🎊🤠
- ·6 t sittenHappy weekend, fam! ❤️ now we can relax and enjoy the weekend, after an eventful week 😃 have never had more faith in Circio, than now! The last half year has tested nerves and wallet, but has been enormously educational. Appreciate all the great posts here, both those that make me smile, and those that share knowledge and useful information. Mostly a fantastic bunch, who are eager to acquire information and knowledge💪 It is clear that this stock tests many people's nerves, and the wise posts in the forum probably help calm many down, so thank you all, for everything you contribute 😘 appreciate you!
- ·7 t sittenHow to invest in Circio: 1. Not know a damn thing about what the company is doing 2. Buy when the stock peaks 3. Sell when the stock hits rock bottom (Repeat points 2. and 3.) 4. Whine in the Nordnet forums
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 9 455 | - | - | ||
| 100 | - | - | ||
| 5 000 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
3 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 1.9. | ||
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 t sittenTHERE ARE MANY STOCKS WITH ENORMOUS UPSIDE. THAT IS NOT WHAT MAKES CIRCIO SPECIAL. 🧬 Find a biotech that can go 20x? Not difficult. The problem is what you usually get with the deal: → One lead program → Short runway → New capital raise around the corner → Limited external validation → Binary clinical risk → And a technology that in practice lives or dies with one indication What's interesting about Circio is the combination. A still small company now has: A platform technology. Extreme preclinical expression data across multiple tissues. 20+ external R&D collaborations. A top-5 pharma that has already taken circVec further in vivo. AAV + LNP + in-vivo cell therapy. And after the capital raise: runway until 2030. It's a rather strange setup. Too much has already happened for this to just be an idea on PowerPoint. But the really big value drivers are still ahead: Disease efficacy. NHP. Paid agreements. Human validation. It is precisely between these two points that the truly asymmetric cases can exist: Enough validation that the technology deserves attention. But still early enough that the market doesn't price in what it could become. Are there other biotechs with enormous upside? Of course. Are there many with exactly this combination of platform + data + Big Pharma interest + optionality + financing, while still being small? There, the list suddenly becomes much shorter. That's why I follow Circio so extremely closely. Not because the outcome is guaranteed. But because such setups don't appear every day. 🧬 We know what we own. 🧱♟️🍷
- ·5 t sitten · MuokattuMany thanks to all contributors here 🙏 You possess a lot of expertise that we benefit from. This is the most exciting Biotech company on OSE. Believe this can multiply several times next year. Unbelievably many positive triggers ahead of us. But remember that negative news briefly pushes the price down. I am long. 💰🇧🇻. I took a nice profit in Wawi and will receive kr 51,678 in dividends from there in a few days, which helps a bit. So I saw I slammed in K500' more into CRNA. I, like you, am a super optimist.⛵⛵⛵Greetings from the skipper 🎊🤠
- ·6 t sittenHappy weekend, fam! ❤️ now we can relax and enjoy the weekend, after an eventful week 😃 have never had more faith in Circio, than now! The last half year has tested nerves and wallet, but has been enormously educational. Appreciate all the great posts here, both those that make me smile, and those that share knowledge and useful information. Mostly a fantastic bunch, who are eager to acquire information and knowledge💪 It is clear that this stock tests many people's nerves, and the wise posts in the forum probably help calm many down, so thank you all, for everything you contribute 😘 appreciate you!
- ·7 t sittenHow to invest in Circio: 1. Not know a damn thing about what the company is doing 2. Buy when the stock peaks 3. Sell when the stock hits rock bottom (Repeat points 2. and 3.) 4. Whine in the Nordnet forums
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 000 | - | - | ||
| 9 455 | - | - | ||
| 100 | - | - | ||
| 5 000 | - | - | ||
| 207 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt